Janux Therapeutics Inc. (JANX)
Janux Therapeutics Statistics
Share Statistics
Janux Therapeutics has 59.11M shares outstanding. The number of shares has increased by 13.99% in one year.
| Shares Outstanding | 59.11M |
| Shares Change (YoY) | 13.99% |
| Shares Change (QoQ) | 2.26% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 49.18M |
| Failed to Deliver (FTD) Shares | 2 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 10.1M, so 17.09% of the outstanding shares have been sold short.
| Short Interest | 10.1M |
| Short % of Shares Out | 17.09% |
| Short % of Float | 30.3% |
| Short Ratio (days to cover) | 14.31 |
Valuation Ratios
The PE ratio is -41.71 and the forward PE ratio is -12.76. Janux Therapeutics's PEG ratio is 13.76.
| PE Ratio | -41.71 |
| Forward PE | -12.76 |
| PS Ratio | 271.8 |
| Forward PS | 4.5 |
| PB Ratio | 2.81 |
| P/FCF Ratio | -65.15 |
| PEG Ratio | 13.76 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Janux Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 59.21, with a Debt / Equity ratio of 0.02.
| Current Ratio | 59.21 |
| Quick Ratio | 59.21 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.23 |
| Debt / FCF | -0.52 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $130.72K |
| Profits Per Employee | $-851.78K |
| Employee Count | 81 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -39.39% in the last 52 weeks. The beta is 3.27, so Janux Therapeutics's price volatility has been higher than the market average.
| Beta | 3.27 |
| 52-Week Price Change | -39.39% |
| 50-Day Moving Average | 31.42 |
| 200-Day Moving Average | 43.72 |
| Relative Strength Index (RSI) | 51.69 |
| Average Volume (20 Days) | 962.37K |
Income Statement
In the last 12 months, Janux Therapeutics had revenue of 10.59M and earned -68.99M in profits. Earnings per share was -1.28.
| Revenue | 10.59M |
| Gross Profit | 10.59M |
| Operating Income | -98.85M |
| Net Income | -68.99M |
| EBITDA | -98.85M |
| EBIT | -98.85M |
| Earnings Per Share (EPS) | -1.28 |
Balance Sheet
The company has 430.61M in cash and 23.02M in debt, giving a net cash position of 407.58M.
| Cash & Cash Equivalents | 430.61M |
| Total Debt | 23.02M |
| Net Cash | 407.58M |
| Retained Earnings | -237.76M |
| Total Assets | 1.06B |
| Working Capital | 1.02B |
Cash Flow
In the last 12 months, operating cash flow was -43.81M and capital expenditures -359K, giving a free cash flow of -44.17M.
| Operating Cash Flow | -43.81M |
| Capital Expenditures | -359K |
| Free Cash Flow | -44.17M |
| FCF Per Share | -0.82 |
Margins
Gross margin is 100%, with operating and profit margins of -933.58% and -651.62%.
| Gross Margin | 100% |
| Operating Margin | -933.58% |
| Pretax Margin | -651.62% |
| Profit Margin | -651.62% |
| EBITDA Margin | -933.58% |
| EBIT Margin | -933.58% |
| FCF Margin | -417.2% |
Dividends & Yields
JANX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for JANX is $72, which is 143.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $72 |
| Price Target Difference | 143.2% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 27.04 |
| Piotroski F-Score | 2 |